Skip to main content
Health Solutions

Prescription drugs

We help navigate pharmacy benefit challenges

Overview

Milliman prescription drugs solutions

PBM contracting and management


Pharmacy plan design


Medicare Part D

Medicare Part D

Insight

Milliman prescription drugs insight

woman in lab
Article

Beyond FDA approval: 5 factors in clinical trial design that influence health insurance coverage decisions

We detail factors in Phase-3 clinical trial design that influence health insurance coverage decisions.

Report

The impact of medication adherence on total healthcare costs for commercially insured patients

A current perspective for patients with diabetes, hypertension, and hyperlipidemia

White paper

Emerging Medicare Advantage and Part D trends from 2024 financial statements

Medicare Advantage (MA) and Part D insurers are citing significant financial headwinds in earnings calls and the press. Statutory financial statements provide insights into emerging trends through year-end 2024.

people in conference room
White paper

Demonstrations and consolidations: A first view of the 2025 PDP market

This article highlights the key changes to premiums and plan offerings in the prescription drug plan (PDP) market.

Research report

Patterns in psychotropic and other select nervous system prescription utilization

Emerging trends in pharmacy shopping and related overdoses

woman looking at prescription bottles
Article

Manage pharmacy spending with precision medicine via uplift modeling

This white paper focuses on one approach for improving drug utilization management: precision medicine through a method known as uplift modeling.

White paper

The evolution of biosimilars in the United States

Biosimilars recently have made significant strides toward greater acceptance and utilization since their first U.S. approval in 2015, although challenges persist.

White paper

Commercial drug trends: 2024 release

This report provides insights into pharmacy cost and utilization trends based on our analysis of the Milliman Consolidated Health Cost Guidelines Sources Database.

White paper

The shifting Medicare landscape: Results from 2024 open enrollment

2024 brings significant changes to the Part D program, resulting in larger than average shifts in member enrollment

White paper

CMS Cell and Gene Therapy Access Model

Exploring the benefits, limitations, and considerations for expansion.

Related products

Milliman prescription drug products

Healthcare analytics
Procurement management

Milliman Payer Network Check

Learn moreNavigation Arrow
Pharmaceutical claims analysis
Pharmaceutical claims analytics

MyRxConsultant

Learn moreNavigation Arrow
Insurance risk assessment
Insurance risk assessment

IntelliScript

Learn moreNavigation Arrow
ACA utilization and cost evaluation
Medicare plan selection solution

Medicare Suggest

Learn moreNavigation Arrow
Premium comparison platform
Cost-saving analysis

Milliman Specialty Pharmacy Insights

Learn moreNavigation Arrow
Healthcare analytics
Price transparency analytics

Milliman Price Transparency Solutions for Payers and Providers

Learn moreNavigation Arrow
Medical underwriting
Healthcare market analysis

Milliman DNA Gene and Cell Therapy Forecasting

Learn moreNavigation Arrow

We’re here to help